Featured Insights and Perspectives from Darwin

The latest insights, ideas, and perspectives from Darwin, updated weekly. Explore a cross-section of up-to-date content from us and other thought leaders on trends in health care, research, and data.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

News and Insights

Showing items 1 to3 of 6

Categories
Tags
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Our Take: Senate’s push to reform PBM practices, increase generic drug competition moves forward as HELP Committee passes new bills
Insight
Our Take Newsletter
May 15, 2023

Our Take: Senate’s push to reform PBM practices, increase generic drug competition moves forward as HELP Committee passes new bills

Learn More
May 15, 2023
gene therapy
generics
drug
drugstore
Our Take: FTC sues to stop Amgen’s acquisition of Horizon Therapeutics, using an untested strategy with potential widespread ramifications
Insight
Our Take Newsletter
May 22, 2023

Our Take: FTC sues to stop Amgen’s acquisition of Horizon Therapeutics, using an untested strategy with potential widespread ramifications

Learn More
May 22, 2023
amgen
fda
Asegua Therapeutics
health
healthcare
Our Take: Missouri’s BJC Healthcare, St. Luke’s announce plans to integrate, forming a $10 billion health system
Insight
Our Take Newsletter
June 5, 2023

Our Take: Missouri’s BJC Healthcare, St. Luke’s announce plans to integrate, forming a $10 billion health system

Learn More
June 5, 2023
health plan
health plans
healthcare
planning
Our Take: Optum makes an unsolicited $3.3 billion bid for Amedisys, potentially starting a bidding war with Option Care Health
Insight
Our Take Newsletter
June 12, 2023

Our Take: Optum makes an unsolicited $3.3 billion bid for Amedisys, potentially starting a bidding war with Option Care Health

Learn More
June 12, 2023
amedisys
funding
Our Take: CMS releases list of 43 Part B drugs flagged for quarterly rebates in IRA program
Insight
Our Take Newsletter
June 19, 2023

Our Take: CMS releases list of 43 Part B drugs flagged for quarterly rebates in IRA program

Learn More
June 19, 2023
CMS
drug
drugcost
drugmaker
Our Take: Embracing the use of ChatGPT with enthusiasm and caution, preferably in equal measure
Insight
Our Take Newsletter
June 26, 2023

Our Take: Embracing the use of ChatGPT with enthusiasm and caution, preferably in equal measure

Learn More
June 26, 2023
artificial intelligence
embright
AI
health
Our Take: Amedisys chooses Optum over Option Care Health in cash deal worth more than $3 billion
Insight
Our Take Newsletter
July 10, 2023

Our Take: Amedisys chooses Optum over Option Care Health in cash deal worth more than $3 billion

Learn More
July 10, 2023
care management
amedisys
health
healthcare
Our Take: Home health industry group sues federal government over rate cuts
Insight
Our Take Newsletter
July 17, 2023

Our Take: Home health industry group sues federal government over rate cuts

Learn More
July 17, 2023
federal
government
health
home
homecare
Our Take: FEATURE: Tracking Teladoc’s ascent to, and continued presence at, the top of the telehealth industry
Insight
Our Take Newsletter
July 14, 2023

Our Take: FEATURE: Tracking Teladoc’s ascent to, and continued presence at, the top of the telehealth industry

Learn More
July 14, 2023
independence health
health
top 5
Our Take: Sanford ends proposal to merge with Fairview based on lack of support by ‘certain stakeholders’
Insight
Our Take Newsletter
July 31, 2023

Our Take: Sanford ends proposal to merge with Fairview based on lack of support by ‘certain stakeholders’

Learn More
July 31, 2023
merger
health
Our Take: CVS Health to lay off 5,000 employees as part of restructuring plan, lowers future earnings outlook
Insight
Our Take Newsletter
August 7, 2023

Our Take: CVS Health to lay off 5,000 employees as part of restructuring plan, lowers future earnings outlook

Learn More
August 7, 2023
CVS
CVS Health
health
cardiology
healthcare
Our Take: Novo Nordisk eyes potential cardiovascular indication for semaglutide, adds CB1 blocker to weight-loss pipeline
Insight
Our Take Newsletter
August 14, 2023

Our Take: Novo Nordisk eyes potential cardiovascular indication for semaglutide, adds CB1 blocker to weight-loss pipeline

Learn More
August 14, 2023
Novo Nordisk
cardiology
health
congestive heart failure
Stay Aware. Stay Informed.

Want to stay ahead of health care trends?

Sign up for highly curated, expert weekly strategic insights for health care executives and leaders.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.